Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.4K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

691
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
691
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

599
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
599
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

709
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
709
Antibiotic Selection00:57

Antibiotic Selection

56.9K
Overview
56.9K
Antimicrobial Proteins01:23

Antimicrobial Proteins

11.9K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibacterial Drugs: The Last Frontier.

ACS infectious diseases·2020
Same author

Personal View of the Antibiotic Value Proposition.

ACS infectious diseases·2020
Same journal

Antimicrobial Peptides and Biofilms: From Molecular Interactions to Therapeutic Control.

ACS infectious diseases·2026
Same journal

Comparative Phenotypic Screening Identifies Protein Synthesis Inhibitors as Compounds That Enhance Early Acidification of <i>Mycobacterium tuberculosis</i> in Macrophages.

ACS infectious diseases·2026
Same journal

Correction to "<i>Treponema pallidum</i> Flagellin FlaB3 Activates Inflammation and Inhibits Autophagy in HMC3 Cells via the TLR4 Pathway".

ACS infectious diseases·2026
Same journal

Coumarin-Mediated Inhibition of Diadenylate Cyclase Correlates with Impaired Biofilm Formation in <i>Streptococcus mutans</i>.

ACS infectious diseases·2026
Same journal

Plasminogen Recruitment by <i>Staphylococcus aureus</i> SdrC Reveals a Tractable Antivirulence Target.

ACS infectious diseases·2026
Same journal

Suilysin of <i>Streptococcus suis</i> Serotype 2 Drives Astrocyte Pyroptosis via Activation of the ROS/NLRP3/Caspase-1/GSDMD Pathway.

ACS infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Nov 6, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.1K

Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility.

David M Shlaes1

  • 1Anti-infectives Consulting, Stonington, Connecticut 06378, United States.

ACS Infectious Diseases
|May 12, 2021
PubMed
Summary
This summary is machine-generated.

Balancing innovation with clinical utility is key for antibacterial discovery and development. Clinical usefulness may outweigh novel targets or chemical classes, reducing development risks.

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.8K

Related Experiment Videos

Last Updated: Nov 6, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.1K
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.8K

Area of Science:

  • Antimicrobial drug discovery and development
  • Pharmaceutical innovation
  • Clinical utility assessment

Background:

  • The landscape of antibacterial discovery necessitates a re-evaluation of value drivers.
  • Traditional metrics of novelty may not align with successful clinical translation.
  • The increasing threat of antimicrobial resistance demands effective therapeutic solutions.

Purpose of the Study:

  • To propose a balanced perspective on antibacterial discovery, development, and commercialization.
  • To emphasize the critical role of clinical utility over mere novelty in antibacterial agents.
  • To explore challenges associated with innovative, non-traditional antibacterial therapies.

Main Methods:

  • This viewpoint synthesizes current trends and challenges in antibacterial research.
  • It analyzes the interplay between scientific novelty and clinical applicability.
  • Considerations for therapeutic integration, including combination therapies and adjunctive use, are discussed.

Main Results:

  • Clinical utility is a more significant driver of value than novel chemical classes or targets.
  • High novelty in antibacterial discovery can increase the risk of scientific or clinical failure.
  • The suitability of novel agents for pharmacokinetic-pharmacodynamic (PK/PD) studies and antimicrobial susceptibility testing (AST) is crucial.

Conclusions:

  • A pragmatic approach balancing innovation with demonstrable clinical utility is essential for advancing antibacterial therapies.
  • The successful development of new antibacterials hinges on their practical application and integration into clinical practice.
  • Evaluating non-traditional approaches requires careful consideration of their therapeutic role and technical feasibility.